Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
VLUE vs XLV: how they differ
VLUE and XLV hold 8% of their weight in the same names, and VLUE returned more over the year.
iShares MSCI USA Value Factor ETF and State Street(R) Health Care Select Sector SPDR(R) ETF.
What they hold in common
By the books each fund has filed, VLUE and XLV hold 8% of their money in the same securities at the same weight.
| Holding | VLUE | XLV |
|---|---|---|
| MERCK & CO., INC. | 1.57% | 5.54% |
| PFIZER INC. | 1.49% | 2.40% |
| CVS HEALTH CORPORATION | 1.11% | 2.30% |
| BRISTOL-MYERS SQUIBB COMPANY | 1.08% | 2.05% |
| THE CIGNA GROUP | 0.84% | 1.27% |
| ELEVANCE HEALTH, INC. | 0.63% | 1.47% |
| CENTENE CORPORATION | 0.31% | 0.53% |
| BIOGEN INC. | 0.27% | 0.56% |
| BECTON, DICKINSON AND COMPANY | 0.16% | 0.73% |
| HUMANA INC. | 0.14% | 0.83% |
| LABCORP HOLDINGS INC. | 0.13% | 0.40% |
| UNIVERSAL HEALTH SERVICES, INC. | 0.10% | 0.14% |
| Only in VLUE | Only in XLV |
|---|---|
| MICRON TECHNOLOGY, INC. 11.63% | Eli Lilly & Co 16.56% |
| INTEL CORPORATION 9.29% | Johnson & Johnson 10.67% |
| CISCO SYSTEMS, INC. 4.97% | AbbVie Inc 7.76% |
| APPLIED MATERIALS, INC. 3.67% | UnitedHealth Group Inc 6.59% |
| GENERAL MOTORS COMPANY 3.16% | Amgen Inc 3.41% |
| VERIZON COMMUNICATIONS INC. 2.66% | Thermo Fisher Scientific Inc 3.25% |
| AT&T INC. 2.53% | Abbott Laboratories 2.76% |
| CITIGROUP INC. 1.94% | Gilead Sciences Inc 2.74% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Jun 30, 2026.
| VLUE iShares MSCI USA Value Factor ETF | XLV State Street(R) Health Care Select Sector SPDR(R) ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | State Street |
| What it is | MSCI USA Value Factor | Health care |
| Total return, 1 year | +69.4% | +20.4% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +51.9 pts | +2.9 pts |
| Expense ratio | 0.15% | 0.08% |
| Already in the S&P 500 | 96.9% | 100.0% |
| Holdings | 148 | 59 |
VLUE in plain words
VLUE is an index equity fund tracking the MSCI USA Value Factor. Over the year to Sep 11, 2026 it returned +69.4% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.15% a year. By its holdings filed for Apr 30, 2026, 97% of the fund by weight is stocks the S&P 500 also holds, across 148 positions, with the top ten at 43.6%.
XLV in plain words
XLV is an index equity fund tracking the Health care. Over the year to Sep 11, 2026 it returned +20.4% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.08% a year. By its holdings filed for Jun 30, 2026, 100% of the fund by weight is stocks the S&P 500 also holds, across 59 positions, with the top ten at 61.7%. It sat 5.9% below its high of Aug 19, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, VLUE or XLV?
- In the year to Sep 12, 2026, with distributions reinvested, VLUE returned +69.4% and XLV returned +20.4%, so VLUE returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, VLUE or XLV?
- VLUE charges 0.15% a year and XLV charges 0.08%, so XLV is cheaper. Fees come from each fund's prospectus.
- How much do VLUE and XLV overlap with the S&P 500?
- By their latest filed holdings, 97% of VLUE and 100% of XLV by weight is stocks the S&P 500 already holds. Between the two funds, 8% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, VLUE against XLV, data as of Sep 12, 2026. https://etfiq.com/compare/any/VLUE-XLV Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources